Amphastar Pharmaceuticals Inc  

(Public, NASDAQ:AMPH)   Watch this stock  
Find more results for Merck, Sharpe & Dohme, Corp
12.04
+0.14 (1.18%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.61 - 12.15
52 week 6.67 - 12.52
Open 11.86
Vol / Avg. 1.26M/170,189.00
Mkt cap 537.57M
P/E     -
Div/yield     -
EPS -0.14
Shares 44.65M
Beta     -
Inst. own 16%
Dec 3, 2014
Amphastar Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Nov 12, 2014
Amphastar Third Quarter Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9.01% 5.16%
Operating margin -13.09% 7.61%
EBITD margin - 13.36%
Return on average assets -5.40% 3.55%
Return on average equity -7.56% 4.89%
Employees 1,217 -
CDP Score - -

Address

11570 6th St
RANCHO CUCAMONGA, CA 91730-6025
United States - Map
+1-909-9809484 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amphastar Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling technically challenging generic and injectable and inhalation products. The Company�s generic product candidates at various development stages that leverage its various technical capabilities, including injectable technologies, including various delivery methods and sizes of pre-filled syringes, vials in solution, suspension and lyophilized forms; inhalation technologies, including metered dose inhalers (MDIs) and metered dose inhalers (DPIs); and analytical technologies. As of May 20, 2014, the Company manufactures and sells 15 products in the United States and is developing a portfolio of 13 generic and seven injectable and inhalation product candidates. In addition to its marketed products, it has a pipeline of 20 generic and product candidates in various stages of development which target a variety of indications.

Officers and directors

Mary Ziping Luo Ph.D Chief Operating Officer, Chief Scientist and Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Jason B. Shandell J.D President, Director
Age: 40
Bio & Compensation  - Reuters
Jack Yongfeng Zhang Ph.D. Chief Executive Officer, Chief Science Officer, Director
Age: 67
Bio & Compensation  - Reuters
William J. Peters Chief Financial Officer, Senior Vice President, Treasurer
Age: 45
Bio & Compensation  - Reuters
Diane Gerst President, Amphastar Nanjing Pharmaceuticals Co., Ltd
Age: 54
Bio & Compensation  - Reuters
Marilyn J. Purchase Corporate Executive Vice President of Operations and President, International Medication Systems, Ltd.
Age: 64
Bio & Compensation  - Reuters
Richard Koo CPA Independent Director
Age: 73
Bio & Compensation  - Reuters
Howard S. Lee Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Floyd F. Petersen Independent Director
Age: 70
Bio & Compensation  - Reuters
Richard Prins Independent Director
Age: 57
Bio & Compensation  - Reuters